Arena Pharmaceuticals Inc. (ARNA) Drops 5.65% on January 06

Equities Staff |

Arena Pharmaceuticals Inc. (ARNA) was one of the Russell 2000's biggest losers for Wednesday January 06 as the stock slid 5.65% to $1.76, a loss of $-0.105 per share. Starting at an opening price of $1.82 a share, the stock traded between $1.75 and $1.86 over the course of the trading day. Volume was 1.26 million shares over 3,751 trades, against an average daily volume of 3.07 million shares and a total float of 242.55 million.

The losses send Arena Pharmaceuticals Inc. down to a market cap of $425.67 million. In the last year, Arena Pharmaceuticals Inc. has traded between $6.28 and $1.60, and its 50-day SMA is currently $1.99 and 200-day SMA is $3.28.

Arena Pharmaceuticals Inc is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs.

Arena Pharmaceuticals Inc. is based out of San Diego, CA and has some 325 employees. Its CEO is Harry F. Hixson.

For a complete fundamental analysis analysis of Arena Pharmaceuticals Inc., check out’s Stock Valuation Analysis report for ARNA. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets


Airbnb is a community marketplace for people to list, discover, and book unique accommodations around the world — online or from a mobile phone. Whether an apartment for a night,…


Snapchat is the fastest way to share a moment with friends. The mobile app, allows users to not only share photos with friends but also control how long they can…